The loss of endothelin-2 exhibits an anticancer effect in A549 human lung adenocarcinoma cell line
Canadian Journal of Physiology and Pharmacology · 01.08.2022 · 100 (8) · 818-827
DOI: 10.1139/cjpp-2022-0006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Physiology and Pharmacology, erschienen am 01.08.2022. Verfasst von Ratih Paramita Suprapto und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical Pharmaceutical Science, Kobe Pharmaceutical University, 4-19-1 Motoyama-Kitamachi, Higashinada, Kobe 658-8558, Japan. Hauptthemen laut MEDLINE: Adenocarcinoma, Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Lung cancer is the leading cause of cancer-related deaths worldwide, and adenocarcinoma is the most common subtype of lung cancer. Endothelin-2 (ET-2) is expressed in the epithelium of alveoli, and its expression is increased in cancer. However, the role of ET-2 in lung adenocarcinoma remains unclear. This study aimed to investigate the pathophysiological functions of ET-2 in A549 human lung adenocarcinoma cells. We analyzed the expression of ET-2 mRNA in lung adenocarcinoma tissues compared with that in nontumor lung tissues using public online databases. The function of ET-2 in A549 cells was investigated using siRNA. ET-2 mRNA level was upregulated in lung adenocarcinoma tissues, and high ET-2 level was associated with poor overall survival in patients with lung adenocarcinoma. ET-2 silencing reduced the proliferation, migration, and invasion, and enhanced apoptosis in A549 cells. Mechanistically, ET-2 silencing reduced the expression levels of X-linked inhibitor of apoptosis and survivin, which are members of the inhibitor apoptosis protein family. In addition, silencing ET-2 inhibited epithelial–mesenchymal transition, which halted migration. Therefore, the specific targeting of ET-2 may be a potential treatment strategy for lung adenocarcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Clinical Pharmaceutical Science, Kobe Pharmaceutical University, 4-19-1 Motoyama-Kitamachi, Higashinada, Kobe 658-8558, Japan.
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki, Chuo, Kobe 650-0017, Japan.
- Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki, Chuo, Kobe 650-0017, Japan.
ORCID-Profile: Noriaki Emoto
Zitieren
APA
Suprapto, R. P., Suzuki, Y., Nagano, T., Hirata, K. I., & Emoto, N. (2022). The loss of endothelin-2 exhibits an anticancer effect in A549 human lung adenocarcinoma cell line. Canadian Journal of Physiology and Pharmacology, 100(8), 818-827. https://doi.org/10.1139/cjpp-2022-0006
Vancouver
Suprapto RP, Suzuki Y, Nagano T, Hirata KI, Emoto N. The loss of endothelin-2 exhibits an anticancer effect in A549 human lung adenocarcinoma cell line. Canadian Journal of Physiology and Pharmacology. 2022;100(8):818-827. doi:10.1139/cjpp-2022-0006
BibTeX
@article{Suprapto2022,
author = {Suprapto, Ratih Paramita and Suzuki, Yoko and Nagano, Tatsuya and Hirata, Ken-Ichi and Emoto, Noriaki},
title = {The loss of endothelin-2 exhibits an anticancer effect in A549 human lung adenocarcinoma cell line},
journal = {Canadian Journal of Physiology and Pharmacology},
year = {2022},
volume = {100},
number = {8},
pages = {818--827},
doi = {10.1139/cjpp-2022-0006}
}
EUVIMED